aod9604 recommended dosage PDF) Peptides: AOD-9604 & BPC-157 AOD-9604 Peptide Guide: Medspa Patient
Description
Commercial development was discontinued in 2007 after the Phase IIb trial failed to meet its primary endpoint
Rare side effects Increased appetite: Paradoxical for a fat loss peptide, but some users report increased hunger
AOD-9604 may be appropriate for individuals seeking research-based approaches to body composition optimization under physician supervision
This selective action means you can dose more aggressively without concerns about the side effects typically associated with growth hormone elevation
